Results 91 to 100 of about 5,000 (229)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Pholiotina cyanopus, a rare fungus producing psychoactive tryptamines

Open Life Sciences, 2014
Pholiotina cyanopus was collected from wood chips and other woody remnants of undetermined tree species. Its basidiomata were found in June within the area of closed sawmill in the central part of Żywiec city (SW Poland).
Halama Marek, Poliwoda Anna, Jasicka-Misiak Izabela, Wieczorek Piotr P., Rutkowski Ryszard   +4 more
doaj   +1 more source

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans [PDF]

, 2016
Ayahuasca is an Amazonian psychotropic plant tea typically obtained from two plants, Banisteriopsis caapi and Psychotria viridis. It contains the psychedelic 5-HT2A and sigma-1 agonist N,N-dimethyltryptamine (DMT) plus ß-carboline alkaloids with ...
Alonso, Joan Francesc, Antonijoan Arbós, Rosa Ma (Rosa María), Barker, Steven, Feilding, Amanda, Friedlander, Pablo, Maqueda, Ana Elda, Mañanas, Miquel Àngel, Rabella, Mireia, Riba, Jordi, Rodríguez-Pujadas, Aina, Romero, Sergio, Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia, Valle, Marta   +12 more
core   +3 more sources

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

An Efficient, Mild and Solvent-Free Synthesis of Benzene Ring Acylated Harmalines

Molecules, 2009
A facile synthesis of a series of benzene ring acylated analogues of harmaline has been achieved by Friedel-Crafts acylation under solvent-free conditions at room temperature using acyl halides/acid anhydrides and AlCl3.
Sabira Begum, Farhat Zubair, Syed Nawazish Ali, Bina Shaheen Siddiqui   +3 more
doaj   +1 more source

Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS [PDF]

Derivatives of N,N-diallyltryptamine (DALT) can be classified as new psychoactive substances. Biotransformation and detectability of 5-fluoro-DALT (5-F-DALT), 7-methyl-DALT (7-Me-DALT), and 5,6-methylenedioxy-DALT (5,6-MD-DALT) are described here.
Brandt, SD, Maurer, HH, Meyer, MR, Michely, JA   +3 more
core   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5- MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn, and LC-HR-MS/MS [PDF]

Many N,N-dialkylated tryptamines show psychoactive properties and were encountered as new psychoactive substances. The aims of the presented work were to study the phase I and II metabolism and the detectability in standard urine screening approaches ...
Brandt, SD, Caspar, AT, Gaab, JB, Maurer, HH, Meyer, MR, Michely, JA   +5 more
core   +1 more source